Rochester General Hospital

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Rochester General Hospital sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Rochester General Hospital: 6 sponsored US clinical trials, none currently recruiting.

Rochester General Hospital sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Secondary Immune Deficiency Disorder, with 1 trials.

Upper-quartile sponsor footprint

Rochester General Hospital sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens

NCT04946084
COMPLETED Phase 2

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

NCT03730129
COMPLETED Phase 2

Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488
TERMINATED Phase 2

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

NCT02341209
COMPLETED Phase 2

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

NCT03211065
TERMINATED Phase 4

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 4 1

Therapeutic Areas

Secondary Immune Deficiency Disorder 1
Aspirin-exacerbated Respiratory Disease 1
Acute Otitis Media 1

How the Rochester General Hospital early-phase archive is shaped

6 indexed studies, none listed as recruiting (0% open); 3 completed (50%).

Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Secondary Immune Deficiency Disorder (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Rochester General Hospital: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Rochester General Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Rochester General Hospital23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Rochester General Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rochester General Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Rochester General Hospital page

6 registered trials is a research-attention snapshot, not an endorsement of Rochester General Hospital or any single study.

  • None of Rochester General Hospital's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Secondary Immune Deficiency Disorder is the condition Rochester General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Secondary Immune Deficiency Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rochester General Hospital pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.